AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06080555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injection
Description: For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
Study NCT06080555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose Injection [Ferinject]
Description: For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
Study NCT05826652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single injection subcostal transversus abdominis plane block
Description: Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
Study NCT05826652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple injection subcostal transversus abdominis plane block
Description: Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
Study NCT04931446 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy/surgical tissue and peripheral blood
Description: Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
Study NCT06553014 — intervention group
Intervention type: OTHER
Intervention: Endovascular Plug Embolization
Description: Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
Study NCT06350045 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PCNL
Description: percutaneous nephrolithotomy
Study NCT06400446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The babies in this group will receive the standard care of the unit. The vital signs and pain scores of the babies will be recorded before the mother's visit for seven days. The vital signs and pain scores of the infants who received the standard care of the unit during one hour, which is the time of the mother's visit, will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
Study NCT06400446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: Kangaroo care will be applied to the experimental group for seven days. Kangaroo care will be started for the babies in the intervention group when the baby is extubated, when the baby starts oral feeding and when the chest incision is closed. Consistent with previous research, mothers will provide skin-to-skin contact for at least 1 hour per day for seven days, starting immediately after feeding. The vital signs and pain scores of the babies will be recorded during the kangaroo care of the mother for seven days. During the kangaroo care, vital signs and pain scores of the infants will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
Study NCT06199440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group III
Description: Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.
Study NCT06153966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION717
Description: ION717 will be administered by IT injection.
Study NCT05414708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
Study NCT03341897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovasculer embolization of varicocele
Description: Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting \< 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise.
Study NCT05909215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
Study NCT05909215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
Study NCT05909215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.5 microgram/kg
Description: Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
Study NCT05909215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.75 microgram/kg
Description: Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
Study NCT06198049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Training
Description: This group will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week
Study NCT06198049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Proprioception Exercises
Description: This group will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
Study NCT05417893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)
Description: The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
Study NCT04827654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weekly produce box and gift card
Description: Weekly box of produce (5-10 lbs) and $10.00 gift card to a local grocery store to purchase preferred produce. If progress on self-goals completed, an additional $10.00 card provided, weekly, for 3 weeks.
Study NCT04935788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk protein
Description: milk protein supplement
Study NCT04935788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micellar casein
Description: micellar casein supplement
Study NCT04935788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pea protein
Description: pea protein supplement
Study NCT04935788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk/pea protein blend
Description: milk/pea protein supplement
Study NCT06176625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication Signage
Description: Signage regarding effective communication strategies posted on door to patient's room.
Study NCT06153966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching ION717 will be administered by IT injection.
Study NCT06454461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG
Description: Upadacinib 15mg once daily for the 8 weeks after NECS
Study NCT05087602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab and Anlotinib
Description: Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study NCT05948657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA-PET CT
Description: Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
Study NCT04671914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid 20 MG/ML Injectable Solution
Description: Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
Study NCT04671914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dilation and curretage
Description: After abortion in II trimester we do D\&C.
Study NCT05039580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
Study NCT05347199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride Pill
Description: Two single low doses amisulpride (100 mg); orally
Study NCT05347199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride Pill
Description: Two single low doses amisulpride (100 mg); orally
Study NCT05347199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two doses, orally
Study NCT05347199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: two doses, orally
Study NCT06185218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Botulinum Toxin
Description: Botulinum Toxin injections will be made into the bladder.
Study NCT05581654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
Study NCT05581654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
Study NCT01927835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: 4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
Study NCT01927835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: ≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM
Study NCT05347069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg/day
Study NCT05347069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aspirin
Description: No aspirin administered
Study NCT01927835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: ≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM
Study NCT01927835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
Study NCT01927835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for DNA/NYVAC/AIDSVAX
Description: Sodium Chloride for injection, 0.9%; administered IM
Study NCT01927835 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA/NYVAC/AIDSVAX
Description: Sodium Chloride for injection, 0.9%; administered IM
Study NCT06176625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Amplifier Use
Description: Patient is provided amplification device and signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
Study NCT05251506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser lancing device or lancet for blood glucose level measurement
Description: Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
Study NCT05251506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser lancing device or lancet for blood glucose level measurement
Description: Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
Study NCT05934487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordella™ Pulmonary Artery Sensor System
Description: The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)
Study NCT06316206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Dienogest 0.03mg/2mg
Description: Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
Study NCT05218408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001 systemic and Intra cavity administration
Description: Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a
Study NCT06545994 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: It's a observational cohort study and no interventions are performed.
Study NCT04925492 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: An imaging method that uses radiotracers to view changes in the metabolic process.
Study NCT04925492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-64]-LLP2A
Description: A radioactive tracer used in PET imaging.
Study NCT04911842 — intervention group
Intervention type: DEVICE
Intervention: HydroMID
Description: Hydrophilic biomaterial
Study NCT04911842 — intervention group
Intervention type: DEVICE
Intervention: TPU
Description: Thermoplastic polyurethane
Study NCT05058469 — intervention group
Intervention type: DEVICE
Intervention: Tracheotomy
Description: Tracheotomy in patients +/- antiplatelet therapy
Study NCT05460936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Functional Training
Description: motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
Study NCT05460936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
Study NCT06421688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
Study NCT06421688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After participants underwent induction of anesthesia, 50 ml of saline was used and pumped using a micro pump at a rate of 25 ml/h.
Study NCT06256211 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study.
Study NCT06156306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.
Study NCT06156306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I combined ACT
Description: In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
Study NCT05334758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Self COVID-19 Antigen Home Test
Description: At home COVID-19 antigen test kit
Study NCT05334758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care COVID-19 Test
Description: Standard of care
Study NCT05334758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR Test
Description: High Sensitivity RT-PCR COVID-19 Test
Study NCT06186739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based motor rehabilitation training participated by caregivers
Description: The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
Study NCT06186739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine self-care
Description: the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.